Pharmafile Logo
Pharmafocus logo
Advanced Search
obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

July 8, 2025
Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …

News

HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure

July 7, 2025
Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure

HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …

News

T-cell therapy – the evolution of cancer treatments

July 7, 2025
CERo therapeutics, Cancer, T cell, immunotherapy

The current forms of immunotherapy, how T cell therapy works and what the future holds

Feature
Astra Zeneca Logo

Purpose and people: the enduring power of brand and the evolution of employer identity

July 7, 2025
Branding, Business Services, Corporate Branding, Medical Communications, Sales and Marketing AstraZeneca, Identity, Inclusion, The Caffeine Partnership, benenden health, branding

Two decades ago, terms like purpose and people were rarely at the forefront of branding conversations. The focus was on …

Feature
Endometriosis - Woman holding stomach in pain

The Problem of Endometriosis in the UK

July 7, 2025
Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology

When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?

Feature
Toast Burning

Five facts about UV exposure and sun safety

July 7, 2025
Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare

1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …

Feature

LEO Pharma appoints Helle Hedegaard Juhl as EVP of global people & corporate affairs

July 7, 2025
Manufacturing and Production Dermatology, Helle Hedegaard Juhl, LEO Pharma, Skin, dermatology

Danish dermatology company, LEO Pharma, announced the appointment of new executive vice president (EVP) of global people and corporate affairs, …

Appointment
Jens Holstein, Alexandra Ogilvie and Ulrich Dauer

Mallia strengthens its advisory board as it accelerates hair loss treatment

July 7, 2025
Manufacturing and Production Dermatology, Skin, biopharma, dermatology, hair loss, mallia

German dermatology company, Mallia Innovations, has appointed Jens Holstein, Alexandra Ogilvie and Ulrich Dauer to its advisory board, strengthening its …

Appointment

FDA grants accelerated approval for advanced non-small cell lung cancer treatment

July 4, 2025
Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …

News

The quiet crisis: why medicines operations matter more than ever in the ICB era

July 4, 2025
Business Services, Market Access Gateway to Local Adoption, Integrated Care Board, NHS, Primary Care Networks, Visions4Health

In the second of the Gateway to Local Access series, Vision4Health caught up with Dr Graham Duce, ICB GP Prescribing …

Feature

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025
Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …

News

Nick Challoner appointed CEO of Ingenza to drive further growth

July 4, 2025
Business Services, Manufacturing and Production CEO, Corporate, Ingenza, contract research development and manufacturing organisation (CRDMO), president

Ingenza, a Scottish contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as chief executive …

Appointment

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025
Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …

News

Ferring strengthens evidence for flexible dosing of follitropin delta in IVF

July 3, 2025
Research and Development Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine

Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to …

News

Carthera receives EMA endorsement for orphan medical device status of SonoCloud

July 2, 2025
Medical Communications, Research and Development Brain disorders, Breakthough Device Designation, CE marking, Carthera, Devices, European Medicines Agency (EMA), Food and Drug Administration, Forfait Innovation Status, Neurology, Orphan Medical Device Status, ultrasound imaging

French biotech company Carthera has announced that its SonoCloud system has been granted orphan medical device status by the European …

News
surgery

SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant

July 1, 2025
Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine

SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …

News

PharmNovo submits CTA for non-addictive neuropathic pain therapeutic

July 1, 2025
Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome

Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …

News
hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025
Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …

News

Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development

June 30, 2025
Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics

Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …

Appointment

Defining neighbourhood working: big picture or local lens?

June 27, 2025
Business Services Gateway to Local Adoption, NHS England, neighbourhood working

In the first of the Gateway to Local Adoption series, Visions4Health caught up with Dr Nick Merrifield to discuss his views on …

Feature
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025